EyePoint Pharmaceuticals (EYPT) reported six-month results from a phase 2 trial of Duravyu to treat diabetic macular edema that met primary and secondary endpoints, but its shares still slumped in premarket trading.
The company said the trial demonstrated "clinically meaningful outcomes," such as continued safety with no Duravyu-related ocular or systemic serious adverse events, and an early and sustained improvement in vision and anatomical control.
EyePoint shares were 23% lower in premarket trading
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.